Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMYL-00w
- Development stage
- Preclinical
- Lead developer
- Amyl Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
AMYL-00w is a preclinical-stage monoclonal antibody being developed by Amyl Therapeutics for the treatment of Alzheimer's disease. It is generated using the company's proprietary Pan-Amyloid Immunotherapy (PAI) platform, which targets the common cross-beta sheet structure found in various misfolded protein aggregates. AMYL-00w specifically targets both Amyloid-beta (Aβ) and Tau protein aggregates, facilitating their clearance from the central nervous system. The antibody is engineered for enhanced brain penetration and is designed to minimize the risk of Amyloid-Related Imaging Abnormalities (ARIA), a significant safety concern associated with first-generation amyloid-targeting therapies.
02
Targets
aggregated α-syn (Alpha-synuclein (α-syn))Cross-β (Cross-beta sheet conformation)Amyloid-beta aggregate (N-terminal epitope)Tau aggregates (Microtubule-associated protein tau (pathological form))
Beyond the preview
Go deeper on AMYL-00w.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMYL-00w.